Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 108Lymphoma, Large B-Cell, Diffuse 97Lymphoma 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Lymphoma, Non-Hodgkin 37Lymphoma, Follicular 37Burkitt Lymphoma 36Leukemia 31Multiple Myeloma 29Lymphoma, Mantle-Cell 26Hodgkin Disease 25Lymphoma, T-Cell, Peripheral 20Lymphoma, Large-Cell, Immunoblastic 15Lymphoma, Large-Cell, Anaplastic 15Lymphoma, B-Cell, Marginal Zone 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasm Metastasis 13Lymphoma, B-Cell 13Leukemia, Lymphocytic, Chronic, B-Cell 12Recurrence 11Neoplasms, Plasma Cell 11Immunoblastic Lymphadenopathy 11Lymphoma, T-Cell 8Dendritic Cell Sarcoma, Interdigitating 8Blast Crisis 8Neoplasms 7Enteropathy-Associated T-Cell Lymphoma 7Waldenstrom Macroglobulinemia 5Primary Myelofibrosis 5Myasthenia Gravis 5

Interventions

Docetaxel 3Prednisone 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1PE regimen 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hormone Refractory Prostate Cancer × Prednisone × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00313482 2012-05-11

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Veeda Oncology

Phase 2 Terminated
35 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡